|Drug Name||GPCR-targeted Project 015|
A first-in-class recombinant antibody targeting Frizzled 8 (Fzd8) receptor is being developed for the treatment of solid tumors. It is expected that the candidate may be developed in combination with standard chemotherapy and targeted therapy.
|Target||Frizzled 8 (FZD8)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||Frizzled 8 modulators|
We look forward to hearing from you.